Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:18:13.058Z.
Calculation as of: 2026-10-06T16:18:13.058Z.
Quote observation: 2026-10-06T16:15:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6b8b16bed2a6fff21aaa666e30465ae2bcbbc8377d0ad77d6381797994f17b37
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Outlook Therapeutics, Inc.
Market Cap
$109.37M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.59M
Operating Cash Flow Yield
N/A
TTM Avg
12.54%
3Y Avg
12.54%
5Y Avg
12.54%
Market Cap
$110.11M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.75M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.02M
Operating Cash Flow Yield
0.67%
TTM Avg
8.27%
3Y Avg
16.31%
5Y Avg
18.05%
Market Cap
$107.65M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.84M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | $109.37M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.59M | N/A | 12.54% | 12.54% | 12.54% |
| Immunic, Inc. (IMUX)vs › | $108.82M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $110.11M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.75M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $111.02M | 0.67% | 8.27% | 16.31% | 18.05% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.65M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $116.34M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.84M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $112.48M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
